Correspondence underscores the need for validated models in guiding surveillance decisions for thin melanoma, suggesting improved outcomes.
This correspondence emphasizes that identifying prognostic factors for recurrence in thin melanoma is only the first step, and that individualized surveillance should be guided by validated multivariable risk prediction models rather than isolated pathological features. It argues that calibration and decision curve analysis are needed to demonstrate whether risk-adapted follow-up provides meaningful clinical benefit beyond statistical significance. Finally, it highlights the need for external validation and contemporary data before these findings are incorporated into routine melanoma surveillance guidelines.
No takes yet. Share an insight, caveat, or question.
Yılmaz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: